# HHS Peptide Policy Review Under RFK Jr.

Canonical source: https://retacompare.com/research/hhs-peptide-policy-review-162

Schedule II & RFK · 2026-02-01


    HHS initiated a formal interagency peptide policy review in summer 2025, bringing together representatives from FDA, NIH, DEA, and HHS's Office of the Assistant Secretary for Health. The review's scope includes the FDA 503A and 503B bulks lists, NIH research funding for peptide science, DEA scheduling of peptide-category substances, and the interaction between compounding law and research peptide commerce. As of early 2026 the review has produced preliminary findings that call for modest expansion of the 503A bulks list and clearer distinction between 'research use only' and compounded-for-administration peptide products. Formal recommendations are expected mid-2026.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources